A comprehensive view of Side Effects/Drug-Related Illnesses. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Teva Pharmaceuticals announces settlement agreement with Attorney General of Florida related to opioid-related claims; Teva will pay US$177M over 15 years and will provide lifesaving Narcan nasal spray valued at US$84M over 10 years
Published: March 30, 2022 by Teva Pharmaceutical Industries Ltd.
AstraZeneca announces approval in Japan for Ondexxya for patients taking Factor Xa inhibitors, which help prevent blood clots but can lead to uncontrolled bleeding; Ondexxya quickly reverses Factor Xa inhibitors in patients experiencing acute bleeding
Published: March 29, 2022 by AstraZeneca AB
Teva Pharmaceuticals reaches agreement with Rhode Island attorney general to settle opioid-related claims; Teva will pay Rhode Island US$21M over 13 years and will provide lifesaving medicine generic Narcan and Suboxone tablets valued at US$78.5M total
Published: March 21, 2022 by Teva Pharmaceutical Industries Ltd.
Major study with millions of participants finds most mRNA COVID-19 vaccine side effects were mild and faded substantially after one day; study relied on data from self-reported instances of negative side effects between December 2020 and June 2021
Published: March 07, 2022 by USA Today Online
Pfizer, under federal judge's orders, releases vaccine safety data previously scheduled to be revealed years later; overall benefit-to-risk ratio remains positive, but new data reportedly show previously unreported deaths occurring after taking vaccine
Published: March 04, 2022 by CE Noticias Financieras

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count